HUGE [NASD]
FSD Pharma Inc.
Index- P/E- EPS (ttm)-1.04 Insider Own9.69% Shs Outstand40.00M Perf Week-2.44%
Market Cap40.10M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float34.58M Perf Month-18.13%
Income-39.00M PEG- EPS next Q- Inst Own1.49% Short Float1.03% Perf Quarter-15.68%
Sales- P/S- EPS this Y58.90% Inst Trans- Short Ratio3.34 Perf Half Y-16.74%
Book/sh1.52 P/B0.53 EPS next Y- ROA-48.90% Target Price- Perf Year-55.56%
Cash/sh0.74 P/C1.08 EPS next 5Y- ROE-57.00% 52W Range0.69 - 1.94 Perf YTD-21.57%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-58.76% Beta0.87
Dividend %- Quick Ratio4.50 Sales past 5Y- Gross Margin- 52W Low15.16% ATR0.07
Employees10 Current Ratio4.50 Sales Q/Q- Oper. Margin- RSI (14)38.76 Volatility12.84% 7.99%
OptionableYes Debt/Eq0.01 EPS Q/Q61.00% Profit Margin- Rel Volume0.41 Prev Close0.80
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume106.95K Price0.80
Recom- SMA20-11.75% SMA50-14.05% SMA200-27.85% Volume47,284 Change-0.02%
Jun-27-22 08:30AM  
Jun-01-22 06:00AM  
May-31-22 08:30AM  
May-24-22 08:30AM  
May-11-22 06:00AM  
May-10-22 03:00AM  
May-06-22 10:41AM  
May-02-22 03:30AM  
Apr-21-22 08:30AM  
Apr-08-22 08:30AM  
Apr-06-22 08:30AM  
Mar-31-22 09:30AM  
Mar-15-22 03:30AM  
Feb-28-22 03:10AM  
Feb-25-22 08:30AM  
Jan-20-22 03:30AM  
Jan-18-22 03:30AM  
Jan-04-22 03:30AM  
Dec-30-21 03:30AM  
Dec-09-21 08:00AM  
Dec-03-21 08:43AM  
03:05AM  
Dec-02-21 04:55PM  
08:00AM  
Nov-16-21 08:30AM  
Oct-19-21 08:30AM  
Oct-18-21 08:35AM  
08:35AM  
Oct-13-21 08:00AM  
Sep-22-21 06:30PM  
03:05AM  
Sep-21-21 09:47AM  
Aug-30-21 11:21AM  
Aug-26-21 11:25AM  
Aug-25-21 01:41PM  
12:03PM  
09:00AM  
07:57AM  
Aug-24-21 04:01PM  
Jul-28-21 10:05AM  
Jul-27-21 08:47AM  
Jun-03-21 09:00AM  
May-26-21 06:59PM  
May-17-21 03:18AM  
May-12-21 12:49PM  
May-10-21 08:30AM  
May-05-21 04:23PM  
08:30AM  
May-03-21 07:30AM  
Apr-26-21 09:04PM  
Apr-23-21 09:00AM  
Apr-05-21 07:30AM  
07:30AM  
Mar-31-21 05:00PM  
Mar-16-21 09:56PM  
Mar-08-21 07:00AM  
07:00AM  
Feb-11-21 08:40AM  
Jan-26-21 07:30PM  
Jan-22-21 04:30PM  
Dec-15-20 08:35AM  
Nov-12-20 05:00PM  
Oct-29-20 07:30AM  
Oct-21-20 07:30AM  
Oct-16-20 07:30AM  
Oct-05-20 07:30AM  
Sep-28-20 02:30AM  
Aug-31-20 02:30AM  
Aug-20-20 05:45AM  
Aug-07-20 05:45PM  
05:45PM  
Aug-06-20 05:00PM  
05:00PM  
Jul-31-20 04:49PM  
09:00AM  
Jul-30-20 02:30AM  
Jul-13-20 02:30AM  
02:30AM  
Jun-23-20 09:00AM  
Jun-22-20 02:30AM  
Jun-09-20 11:39AM  
05:47AM  
Jun-04-20 09:43AM  
Jun-03-20 04:20PM  
02:30AM  
02:30AM  
May-21-20 08:30AM  
08:30AM  
May-14-20 05:12PM  
Mar-23-20 09:17AM  
Mar-10-20 09:00AM  
Mar-09-20 08:30AM  
08:30AM  
Mar-06-20 01:14PM  
Mar-04-20 02:30AM  
02:30AM  
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.